News

Around 60 individuals will be included in this multi-center, randomized, double-blind, placebo-controlled, two arm, parallel group Phase II trial of ADS-5102. During the trial, all patients will be

The trial did not meet its primary objective to show superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebo. The company said that this is the first

BIND is a clinical-stage nanomedicine company that develops targeted and programmable therapeutics called Accurins. Following achievement of proof-of-concept, both the firms intend to expand the collaboration to develop

Last year, the company secured orphan drug designation from the US Food and Drug Administration (FDA) for Epidiolex to treat LGS. The company intends to report top-line data

The drug is approved for these children who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Earlier in 2008, the FDA approved Promacta for use in

The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson’s disease. "This recent patent award will provide robust protection for MLR-1019

In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES

The product candidate is developed for the indications of refractory and tophaceous gout, which result from elevated levels of uric acid within the body that cause debilitating pain

OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated